Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis (NCT01684345) | Clinical Trial Compass
TerminatedPhase 3
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
United States200 participantsStarted 2012-08
Plain-language summary
The purpose of this study is to evaluate the efficacy of gevokizumab in the treatment of active non-infectious intermediate, posterior, or pan- uveitis.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosis of non-infectious intermediate, posterior, or pan- uveitis in at least one eye
* Active uveitic disease in at least one eye
* Currently on one of the following stable treatment regimens for uveitis: oral corticosteroids; systemic immunosuppressive medication; a combination of oral corticosteroids with at least one systemic immunosuppressive medication
* Effective contraceptive measures
Exclusion Criteria:
* Infectious uveitis and masquerade syndromes
* Isolated anterior uveitis
* Contraindication to mydriatics
* History of allergic or anaphylactic reactions to monoclonal antibodies
* Active tuberculosis disease
* History of recurrent infection or predisposition to infection; active ocular infection
* Pregnant or nursing women
Other protocol-defined inclusion/exclusion criteria may apply